MUROMACHI CHEMICALS INC. (4885) Stock Price

Muromachi Chemical operates across three core business pillars: pharmaceutical active ingredients, health foods, and chemical products. The company handles the import, synthesis, and purification of active ingredients, as well as quality testing. It also plans and manufactures health foods such as stick jellies on a contract basis, and produces water treatment products using ion exchange resins and separation membranes, along with various contract manufacturing services.

The company serves a diverse customer base including domestic pharmaceutical companies, pharmaceutical distributors, health food mail-order and manufacturers, chemical makers, and machinery manufacturers. It maintains an in-house system for sourcing raw materials from overseas, processing, and analysis. Revenue is generated through product sales as well as contract manufacturing and equipment and material sales.

Operations are divided into three segments: the pharmaceutical business (sales, manufacturing, and purification of active ingredients, and handling of radioisotopes); the health food business (planning and manufacturing of stick and pouch jellies through ODM); and the chemical business (sales and regeneration of ion exchange resins and separation membranes, design and manufacturing of pure water systems, and contract manufacturing including amino acid purification and AdBlue® production). The company's strength lies in its in-house analytical, testing, and processing equipment, which enables material selection and processing tailored to specific applications, thereby adding value to its offerings.

The company is withdrawing from its health food business (targeting May 2026) to concentrate management resources on two core pillars: pharmaceuticals and chemicals, aiming for sustainable growth. Long-term targets for the fiscal year ending May 2032 include sales of 10 billion yen and an operating profit margin of 10% or higher. For the medium term, the "Medium-Term Management Plan 2028" sets targets for the fiscal year ending May 2028 of sales of 7.2 billion yen or higher, operating profit of 360 million yen or higher, EBITDA of 650 million yen or higher, and return on equity (ROE) of 10% or higher. On the financial side, the company prioritizes maintaining equity ratio (currently 46.6%) and stable dividends, balancing capital efficiency with financial soundness.

Priority investment areas are strengthening manufacturing capacity and quality control. The company is pursuing stable supply and cost reduction through capital expenditure and automation equipment deployment. In pharmaceuticals, the company is diversifying raw material sourcing across multiple regions to mitigate country risk, while expanding production lines and inspection systems to ensure smooth execution of new development projects. In chemicals, the company is focusing on application development leveraging liquid treatment technology and ion exchange resins, differentiating itself through in-house material selection, analysis, and processing capabilities.

New market development centers on overseas expansion and partnerships. The company is actively pursuing joint development with overseas resin manufacturers and others, developing applications addressing social issues such as water treatment, while expanding new sales channels including overseas markets. Resources and factory space freed by the health food business withdrawal will be redirected toward manufacturing capacity expansion and pharmaceutical contract manufacturing projects, strengthening the revenue base through expanded contract manufacturing and equipment and material sales.

On technological innovation, the company continues investing in both research and development and production technology, establishing systems for rapid market entry of new products through enhanced analytical and testing equipment and standardized startup processes. While automation and production efficiency improvements stabilize quality, the company is strengthening technical and operational capabilities through improved recruitment, training, and evaluation systems, and pursuing technology transfer and faster product commercialization through joint research with partners.